

SOFTWARE

CHIPME

8.05.2014

I am excited to be part of a new COST action So far only [the EU description](#) has been on-line while now also the brandnew website can be reached at chipme2.promoscience.com (twitter channel is @IS1303CHIPME).

CHIP ME - IS1303
Citizen's Health through public-private Initiatives: Public health, Market and Ethical perspectives (COST Action IS1303)

CHIPme is
a community of researchers and stakeholders to promote public-private initiatives in public health genomics

ETHICS LAW SCIENCE

REVIEW
Research, development and clinical implementation and use of genetic tests and genetic screening programs - Seven prevalent misapprehensions
by Jan Helge Solbakk on March 1st, 2014

OPINION
Over-the-counter genetic testing services
by George P. Patrinos on March 1st, 2014

the WORKING GROUPS
RESEARCH & ETHICS
GENOMICS & MARKETS
SCIENCE & VALUES

CHIPME NEWS
April 2nd, 2014
First CHIP ME articles available
March 7th, 2014
1st CHIP ME Working Group

From the official project description

The falling cost of genome sequencing is making genetic information more easily accessible to the ordinary citizen. The proliferation of different actors in COST countries and beyond, engaging with the generation and interpretation of genetic data represents a tremendous opportunity but also a new challenge for society. The public health care system will increasingly be asked to provide interpretation and counselling relating to genetic information that has been generated privately and to satisfy the legitimate curiosity of participants in large-scale population genetic research. Existing ethical and regulatory frameworks may not be suitable to allow an efficient and ethical meeting of demand and supply of genetic knowledge and health, as well as a virtuous interaction between public and private actors. This Action aims to improve the state of the art by creating a community of researchers and stakeholders and linking existing initiatives which bring critical expertise in bioethics, social studies of science and technology, genetic technology, information and communication technology, stakeholder deliberation, and patient centred initiatives (PCI).